ImmuCell Corporation (ICCC) Spending and interest coverage
- R&D / revenue · 12 months: Value 6.16%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.81%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 6.16% | Research and development expense / revenue. Period ending 2026-06-30. $1.89M ÷ $30.68M × 100 ≈ 6.16% |
| Stock-based compensation / revenue · 12 months | 1.81% | Share-based compensation / revenue. Period ending 2026-06-30. $554.76K ÷ $30.68M × 100 ≈ 1.81% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.89M USD | Research and Development Expense |
| Revenue | 30.68M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 554.76K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 3.87M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.89M | $30.68M | $554.76K | $3.87M | (m) | 6.16% | 1.81% | (m) | (m) |
| 2026-03-31 | $2.60M | $29.93M | $381.61K | $2.50M | (m) | 8.69% | 1.27% | (m) | (m) |
| 2025-12-31 | $3.04M | $27.64M | $295.87K | $1.65M | (m) | 11.00% | 1.07% | (m) | (m) |
| 2025-09-30 | $3.10M | $27.77M | $260.95K | $2.33M | (m) | 11.17% | 0.94% | (m) | (m) |
| 2025-06-30 | $3.19M | $28.27M | $265.35K | $1.73M | (m) | 11.30% | 0.94% | (m) | (m) |
| 2025-03-31 | $3.39M | $27.30M | $296.66K | $-222.48K | (m) | 12.43% | 1.09% | (m) | (m) |
| 2024-12-31 | $3.90M | $26.49M | $325.55K | $-1.64M | (m) | 14.72% | 1.23% | (m) | (m) |
| 2024-09-30 | $4.15M | $23.84M | $357.35K | $-3.27M | $584.95K | 17.39% | 1.50% | -5.58× | Reported |
| 2024-06-30 | $4.48M | (m) | $376.22K | $-3.87M | $585.42K | (m) | (m) | -6.62× | Reported |
| 2024-03-31 | $4.55M | (m) | $353.86K | $-3.79M | $531.62K | (m) | (m) | -7.13× | Reported |
| 2023-12-31 | $4.39M | $17.47M | $368.87K | $-5.75M | $475.60K | 25.15% | 2.11% | -12.09× | Reported |
| 2023-09-30 | $4.38M | $16.29M | $333.60K | $-6.38M | $416.83K | 26.88% | 2.05% | -15.30× | Reported |
| 2023-06-30 | $4.53M | (m) | $322.29K | $-5.81M | $361.64K | (m) | (m) | -16.07× | Reported |
| 2023-03-31 | $4.57M | (m) | $308.27K | $-5.13M | $363.31K | (m) | (m) | -14.11× | Reported |
| 2022-12-31 | $4.49M | (m) | $266.24K | $-2.30M | $348.54K | (m) | (m) | -6.60× | Reported |
| 2022-09-30 | $4.53M | $20.10M | $241.78K | $-519.78K | (m) | 22.56% | 1.20% | (m) | (m) |
| 2022-06-30 | $4.31M | (m) | $202.15K | $590.48K | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $4.17M | (m) | $163.78K | $1.42M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $4.17M | (m) | $144.31K | $257.38K | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $4.25M | (m) | $160.08K | $-522.39K | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $4.32M | (m) | $176.99K | $-1.05M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $4.41M | (m) | $210.36K | $-1.95M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $4.35M | (m) | $253.13K | $-1.38M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $4.16M | (m) | $288.01K | $-988.45K | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $4.02M | (m) | $294.27K | $-1.17M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $3.75M | (m) | $307.71K | $-1.02M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $3.69M | (m) | $313.14K | $-953.91K | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $3.98M | (m) | $307.89K | $-1.64M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $3.90M | (m) | $328.94K | $-1.36M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $3.84M | (m) | $355.80K | $-1.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $3.52M | (m) | $344.02K | $-1.45M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $2.99M | (m) | $309.44K | $-934.04K | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $2.66M | (m) | $266.66K | $-1.27M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $2.29M | (m) | $224.07K | $-1.34M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $2.05M | (m) | $199.78K | $-242.84K | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $1.57M | (m) | $165.12K | $289.80K | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $1.29M | (m) | $139.56K | $822.68K | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $1.28M | (m) | $105.25K | $1.11M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $1.24M | (m) | $67.40K | $890.20K | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $1.32M | (m) | $55.71K | $1.23M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $1.32M | (m) | $40.69K | $1.81M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $1.21M | (m) | $27.65K | $2.00M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $1.24M | (m) | $23.22K | $2.12M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $1.37M | (m) | $25.56K | $1.86M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $1.43M | (m) | $24.20K | $1.27M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $1.92M | (m) | $27.12K | $601.09K | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $2.18M | (m) | $30.00K | $-206.40K | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $2.04M | (m) | $29.36K | $-615.23K | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $1.97M | (m) | $32.33K | $-816.05K | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $1.48M | (m) | $30.34K | $-333.66K | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $1.15M | (m) | $31.36K | $-19.55K | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $1.06M | (m) | $32.77K | $202.92K | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $996.42K | (m) | $34.29K | $276.76K | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $936.27K | (m) | $35.71K | $290.43K | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $917.60K | (m) | $35.98K | $245.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $954.36K | (m) | $37.62K | $241.88K | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $1.03M | (m) | $38.45K | $135.62K | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $1.50M | (m) | $38.92K | $-334.63K | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $1.72M | (m) | $38.17K | $-632.73K | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $1.49M | (m) | $29.51K | $-690.28K | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $1.64M | (m) | $94.06K | $-529.91K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |